Trials / Not Yet Recruiting
Not Yet RecruitingNCT07398950
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through comparison with technetium-99m pyrophosphate (PYP) imaging results.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ATTR-CM AI-ECG and AI-Echo Model | AI-based sequential screening approach for ATTR-CM |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07398950. Inclusion in this directory is not an endorsement.